Mirati Therapeutics
Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio
Mirati Therapeutics, long speculated to be a potential acquisition target in the world of Big Pharma, has now sealed a ...
Amgenās Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Amgen’s groundbreaking KRAS inhibitor, Lumakras, faced a pivotal moment as the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened to evaluate ...
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
Mirati fires its CEO and announces a new lung cancer Krazati-Keytruda study strategy
Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...
Mirati’s KRAS Inhibitor Krazati Faces Rejection in Europe
Source – Mirati Therapeutics Mirati Therapeutics has faced a setback in its quest to market its lead KRAS inhibitor Krazati, ...
